46LOW

BDX

BCAL FPO [BDX]
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Healthcare · ASX Small Cap
$0.1000 +5.3%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical66
Catalyst53
Sentiment50
Fundamental34
Momentum75
Risk Gate50
Get alerts when BDX's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track BDX — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Trading above the 200-day average — the long-term trend is on your side
  • Low cash runway (2 quarters) - dilution risk
  • Moderate P/S ratio (13.8x)
  • Small-cap ($20-100M)
  • Capital raise activity (1 events)
  • CANSLIM S: Tight float (48%)
  • Sentiment is mixed — no strong consensus either way
  • Strong long-term momentum — up 60% over the past year (excluding last month)
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.83%/day)
  • RBA hiking (-3pts)

Risk Signals

  • Revenue declining (-8%)
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-282%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about BDX
"What's driving BDX's score?" "How does BDX compare to peers?" "Key risks for BDX?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE BCAL Accelerates Rollout of Avantect Early Detection Tests
NONE Change of Director's Interest Notice
NONE Change of Director's Interest Notice
Announcement tone +3pts

Recent ASX Announcements

2026-03-25 BCAL Accelerates Rollout of Avantect Early Detection Tests PRICE SENSITIVE
2026-03-20 Change of Director's Interest Notice
2026-03-19 Change of Director's Interest Notice
2026-03-17 Change of Director's Interest Notice
2026-03-06 Cleansing Notice

Key Metrics

$35.0M
Market Cap
217K
Avg Volume
1.0x
Vol Ratio
$0.05 — $0.15
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-121.7%
ROE
-282.1%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 48%
LLeader vs LaggardlaggardRS: -1
IInstitutional SponsorshipweakInst: 3%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #63 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:BDX vs ATXBDX vs PNVBDX vs IMM
Scout Pro — Deeper Analysis for BDX
Try Pro free for 30 days
Share this analysis

Track BDX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required